Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2 2

Status

Unknown 6Recruiting 4Not yet recruiting 3Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Non-squamous NSCLC 1HER2-positive Breast Cancer 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × pyrotinib × Clear all
NCT04447118 2025-12-19

PYRAMID-1

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
151 enrolled
Thoracic

Non-squamous NSCLC

NCT03588091 2025-08-22

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
355 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡